Literature DB >> 11972645

Recurrence of renal cell carcinoma more than 5 years after nephrectomy.

Kohsuke Uchida1, Noriomi Miyao, Naoya Masumori, Atsushi Takahashi, Toshiro Oda, Masahiro Yanase, Hiroshi Kitamura, Naoki Itoh, Masaaki Sato, Taiji Tsukamoto.   

Abstract

OBJECTIVES: We evaluated clinical features and predictive factors for the recurrence of renal cell carcinoma (RCC) developing more than 5 years after nephrectomy.
METHODS: We retrospectively reviewed 239 patients with RCC who underwent surgery for the primary lesion. To identify factors that affected recurrence more than 5 years after nephrectomy (delayed recurrence) and its clinical outcomes, we performed a multivariate analysis using Cox's proportional hazards model and a survival study.
RESULTS: Recurrence developing within 5 years after nephrectomy (early recurrence) was found in 57 patients and delayed recurrence in 11 patients. The multivariate analysis revealed no clinical and pathologic features influencing delayed recurrence in 114 patients who survived more than 5 years after nephrectomy without having early recurrence. The patients with delayed recurrence showed better clinical outcomes than those with early recurrence when the rate was determined from the time of recurrence.
CONCLUSIONS: Although delayed recurrence is not a rare event for patients with RCC, no clinical and pathologic factors at the time of the initial treatment can predict the recurrence. Patients who are free of recurrence for more than 5 years after surgery for a primary lesion should be carefully followed up for delayed recurrence.

Entities:  

Mesh:

Year:  2002        PMID: 11972645     DOI: 10.1046/j.1442-2042.2002.00418.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  15 in total

1.  Solitary colonic metastasis from renal cell carcinoma presenting as a surgical emergency nine years post-nephrectomy.

Authors:  Alka M Jadav; Sri G Thrumurthy; Bernard A DeSousa
Journal:  World J Surg Oncol       Date:  2010-06-29       Impact factor: 2.754

2.  Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma.

Authors:  Yoichi Fujii; Masaomi Ikeda; Kazuhiro Kurosawa; Mariko Tabata; Takayuki Kamigaito; Chihiro Hosoda; Toshikazu Okaneya
Journal:  Int J Clin Oncol       Date:  2014-12-02       Impact factor: 3.402

Review 3.  The clinical implications of the genetics of renal cell carcinoma.

Authors:  Inger Rosner; Gennady Bratslavsky; Peter A Pinto; W Marston Linehan
Journal:  Urol Oncol       Date:  2009 Mar-Apr       Impact factor: 3.498

4.  Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.

Authors:  Y Homma; K Kawabe
Journal:  World J Urol       Date:  2004-09-29       Impact factor: 4.226

5.  Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment.

Authors:  Yuki Kyoda; Ko Kobayashi; Megumi Hirobe; Tetsuya Shindo; Fumimasa Fukuta; Kohei Hashimoto; Toshiaki Tanaka; Akiko Tonooka; Hiroshi Kitamura; Satoshi Takahashi; Naoya Masumori; Tadashi Hasegawa; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2013-02-13       Impact factor: 3.402

6.  Familial renal cancer: molecular genetics and surgical management.

Authors:  Glen W Barrisford; Eric A Singer; Inger L Rosner; W Marston Linehan; Gennady Bratslavsky
Journal:  Int J Surg Oncol       Date:  2011-08-22

7.  Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?

Authors:  Sang Hyub Lee; Hee Seo Son; Seok Cho; Sang Jin Kim; Dae Seon Yoo; Seok Ho Kang; Sung Yul Park; Jinsung Park; Sung-Goo Chang; Seung Hyun Jeon
Journal:  Cancer Res Treat       Date:  2014-11-17       Impact factor: 4.679

8.  Treatment outcome of radiation therapy and concurrent targeted molecular therapy in spinal metastasis from renal cell carcinoma.

Authors:  Sangjoon Park; Kyung Hwan Kim; Woo Joong Rhee; Jeongshim Lee; Yeona Cho; Woong Sub Koom
Journal:  Radiat Oncol J       Date:  2016-06-17

9.  The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features.

Authors:  Lu Wang; Yun Cui; Lian Zhang; Jindong Sheng; Yang Yang; Guanyu Kuang; Yu Fan; Qian Zhang; Jie Jin
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

10.  Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.

Authors:  Wan-Xiang Zheng; Fei Yan; Qin Xue; Guo-Jun Wu; Wei-Jun Qin; Fu-Li Wang; Jun Qin; Chun-Juan Tian; Jian-Lin Yuan
Journal:  Onco Targets Ther       Date:  2015-08-10       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.